Pfizer Inc. Press Releases https://investors.pfizer.com/generated by Q4Mon, 24 Aug 2026 14:54:49 -0400Copyright Q4 Inc. All rights reserved.Pfizer and Valneva’s Lyme Disease Vaccine Candidate Marketing Authorization Application Validated by European Medicines Agency728c92b2-e5b3-4e7f-95a4-851556861a88https://investors.pfizer.com/Investors/news-events/News/news-details/2026/Pfizer-and-Valnevas-Lyme-Disease-Vaccine-Candidate-Marketing-Authorization-Application-Validated-by-European-Medicines-Agency/default.aspxFri, 14 Aug 2026 00:00:00 -0400Pfizer Reports Second-Quarter Results And Raises Midpoint of 2026 Revenue Guidance4b1c9ca0-4e21-4713-966e-76e4584add3bhttps://investors.pfizer.com/Investors/news-events/News/news-details/2026/Pfizer-Reports-Second-Quarter-Results-And-Raises-Midpoint-of-2026-Revenue-Guidance/default.aspxTue, 04 Aug 2026 06:45:00 -0400Pfizer Announces Positive Topline Phase 3 Results for LITFULO in Patients with Nonsegmental Vitiligo0e91d6f2-8081-4f79-9ad9-a26099d88a94https://investors.pfizer.com/Investors/news-events/News/news-details/2026/Pfizer-Announces-Positive-Topline-Phase-3-Results-for-LITFULO-in-Patients-with-Nonsegmental-Vitiligo/default.aspxThu, 30 Jul 2026 06:45:00 -0400European Commission Authorizes Pfizer and BioNTech XFG-adapted COVID-19 Vaccine in the European Unionbddaca50-0e7a-4e9e-bf93-68291071e85ehttps://investors.pfizer.com/Investors/news-events/News/news-details/2026/European-Commission-Authorizes-Pfizer-and-BioNTech-XFG-adapted-COVID-19-Vaccine-in-the-European-Union/default.aspxWed, 29 Jul 2026 16:30:00 -0400FDA Grants Priority Review for Pfizer’s TALZENNA Plus XTANDI for the Treatment of Metastatic Prostate Cancer78120731-395b-4326-9787-ded62b98b508https://investors.pfizer.com/Investors/news-events/News/news-details/2026/FDA-Grants-Priority-Review-for-Pfizers-TALZENNA-Plus-XTANDI-for-the-Treatment-of-Metastatic-Prostate-Cancer/default.aspxWed, 22 Jul 2026 16:30:00 -0400U.S. FDA Approves PADCEV® plus Keytruda® as Neoadjuvant and Adjuvant Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibilityc49246f8-963d-4061-8608-7facf0ea1ee4https://investors.pfizer.com/Investors/news-events/News/news-details/2026/U-S--FDA-Approves-PADCEV-plus-Keytruda-as-Neoadjuvant-and-Adjuvant-Treatment-for-Muscle-Invasive-Bladder-Cancer-Regardless-of-Cisplatin-Eligibility/default.aspxFri, 10 Jul 2026 11:23:00 -0400Pfizer Declares Third-Quarter 2026 Dividendfc2cb221-1792-4747-82e3-48d8cce2a497https://investors.pfizer.com/Investors/news-events/News/news-details/2026/Pfizer-Declares-Third-Quarter-2026-Dividend/default.aspxWed, 24 Jun 2026 15:52:00 -0400FDA Approves Pfizer’s IBRANCE Regimen for HR+, HER2+ Metastatic Breast Cancer Frontline Maintenance65c761b5-5f36-42f2-a649-654adbdb9146https://investors.pfizer.com/Investors/news-events/News/news-details/2026/FDA-Approves-Pfizers-IBRANCE-Regimen-for-HR-HER2-Metastatic-Breast-Cancer-Frontline-Maintenance/default.aspxWed, 24 Jun 2026 14:10:00 -0400Pfizer Invites Public to View and Listen to Webcast of August 4 Conference Call with Analysts4aad6983-402e-489b-913a-23ea37ac4e10https://investors.pfizer.com/Investors/news-events/News/news-details/2026/Pfizer-Invites-Public-to-View-and-Listen-to-Webcast-of-August-4-Conference-Call-with-Analysts/default.aspxTue, 23 Jun 2026 10:00:00 -0400Pfizer Announces Topline Phase 3 Results for Sigvotatug Vedotin in Previously Treated Metastatic Non-Squamous Non-Small Cell Lung Cancer1e3b074e-9ea5-4e70-9f7e-914731fdee5chttps://investors.pfizer.com/Investors/news-events/News/news-details/2026/Pfizer-Announces-Topline-Phase-3-Results-for-Sigvotatug-Vedotin-in-Previously-Treated-Metastatic-Non-Squamous-Non-Small-Cell-Lung-Cancer/default.aspxMon, 22 Jun 2026 16:30:00 -0400